Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.

Second-line ceritinib treatment, when administered at 450 mg/day with food, is both well tolerated and efficacious in a patient with previously treated lung adenocarcinoma who had discontinued crizotinib due to disease progression and gastrointestinal adverse effects (AEs).